Novartis India is fundamentally a pharmaceutical trading house - it buys finished medicines from its Swiss parent and sells them to Indian hospitals and distributors, owning no factories of its own. Incorporated in 1947 and operating in India for over 75 years, the company was a subsidiary of Novartis AG, Switzerland until February 2026, when the parent agreed to sell its entire 70.68% stake to the ChrysCapital private equity group, triggering a change of control and a proposed name change. Its recurring approach has been to differentiate branded medicines in a market dominated by cheap generics through scientific engagement with doctors - using targeted digital campaigns, continuing medical education, and partnerships with medical associations - while progressively shifting to an asset-light model that outsources distribution of its largest brands to Dr. Reddy's Laboratories. # Business segments A single pharmaceutical trading engine, split into two go-to-market streams - a direct scientific-marketing arm for specialist transplant and neurology medicines, and an outsourced distribution arm for mass-market pain and calcium brands. ## 1. Specialist medicines: branded drugs sold on scientific trust **The company imports high-value immunosuppressants and neurology drugs from its Swiss parent and sells them to Indian hospitals and distributors, competing against cheap generics by building deep relationships with transplant surgeons and neurologists.** - **Imported, not manufactured** - all products are sourced as finished goods from Novartis Pharma AG, Switzerland, a related party that supplied 40.50% of total purchases in FY24; without this supply line, the brands would not be available for sale in India. - **Differentiated through doctor engagement** - the company runs in-clinic campaigns like 'My Trust with Myfortic' and 'Start Early with Certican', sends Rep Triggered Emails to physicians, and partners with bodies like the European Renal Association for International Speaker Programs, because in a market where generics are 75% of the industry, brand recall among specialists is the only moat. - **Transplant is the growth engine** - the immunosuppressant portfolio (Simulect, Certican, Sandimmun, Neoral, Myfortic) grew 14% in FY25 despite supply constraints on Simulect, and had already grown 23% in FY23, driven by a strategy focused on preventing infections in transplant patients that resonated with surgeons. - **Neurology is a mature anchor** - the neurosciences portfolio includes Tegrital for epilepsy and the Exelon Patch for Alzheimer's dementia, though the segment was hit when the revised National List of Essential Medicines in 2022 imposed price caps on nine of the company's brands, mostly in neurology and oncology. - **Sold through a concentrated distributor network** - in FY24, 96.10% of sales went through 2,134 dealers and distributors, with the top 10 accounting for 63.90% of those sales, and no single customer crossing 10% of total revenue. ## 2. Established medicines: mass-market brands distributed by a partner **The Voveran pain-relief range, the Calcium range, and Methergine are sold through an exclusive distribution deal with Dr. Reddy's Laboratories, trading direct control for wider reach.** - **Outsourced field force** - since FY22, Dr. Reddy's has handled sales and distribution of these brands across wider geographies through its own expanded field force, while Novartis AG retains trademark ownership and Novartis India earns revenue without deploying its own sales reps. - **Voveran is the flagship** - the brand ranks among the top three in the Indian NSAID (non-steroidal anti-inflammatory drug) market, with its sustained-release range making up 91% of the oral portfolio, and the company runs consumer-facing campaigns like 'Stronger than Pain' and 'The Cool Movement' for the Emulgel version. # Group structure and partners **The company is being sold by its Swiss parent to a private equity group with an existing Indian pharma portfolio, in a transaction that will change its name, its board, and potentially its commercial agreements.** - **Swiss parent exits** - Novartis AG held 70.68% of the equity until February 2026, when it signed a Share Purchase Agreement to sell its entire stake to three ChrysCapital entities for approximately INR 1,445.89 crores, triggering a mandatory open offer for another 26% at INR 860.64 per share. - **ChrysCapital brings pharma know-how** - the acquirer is a private equity group that has raised about USD 8.5 billion over 26 years and already owns stakes in Indian pharma companies including Corona Remedies, Eris Lifesciences, and Intas Pharmaceuticals. - **Transitional commercial agreements likely** - Novartis AG or its affiliates may enter into licensing or assignment deals for intellectual property rights to facilitate the handover, which matters because the company's entire product supply currently depends on the Swiss parent. - **Dr. Reddy's remains the distribution partner** - the exclusive sales and distribution arrangement for the Voveran range, Calcium range, and Methergine, entered into in FY22, was in its third year of operations by FY25 and is not contingent on the ownership change.